Graves et al., 2019 - Google Patents
Development and characterization of a canine-specific anti-CD94 (KLRD-1) monoclonal antibodyGraves et al., 2019
View HTML- Document ID
- 9540873228676593718
- Author
- Graves S
- Gyurkocza B
- Stone D
- Parker M
- Abrams K
- Jochum C
- Gallo S
- Saad M
- Johnson M
- Rosinski S
- Storb R
- Publication year
- Publication venue
- Veterinary immunology and immunopathology
External Links
Snippet
Natural killer (NK) cells are non-T, non-B lymphocytes are part of the innate immune system and function without prior activation. The human NK cell surface determinant, CD94, plays a critical role in regulation of NK cell activity as a heterodimer with NKG2 subclasses. Canine …
- 241000282465 Canis 0 title abstract description 81
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7062720B2 (en) | Methods and compositions for cell immunotherapy | |
DK1648507T3 (en) | PROCEDURES AND COMPOSITIONS FOR INCREASING THE EFFECTIVENESS OF THERAPEUTIC ANTIBODIES USING COMPOUNDS THAT POTENTATE NK CELLS | |
JP7352473B2 (en) | Methods and compositions for chimeric antigen receptors targeting cancer cells | |
JP7284707B2 (en) | Engineered Cells Expressing Prostate-Specific Membrane Antigen (PSMA) or Modified Forms Thereof and Related Methods | |
CN107206025A (en) | The method and composition treated for adoptive cellular | |
CN108884140A (en) | The Chimerical receptor of modification and compositions related and method | |
Graves et al. | Development and characterization of a canine-specific anti-CD94 (KLRD-1) monoclonal antibody | |
CN112534044A (en) | Modified pluripotent stem cells and methods of making and using | |
CN108472346A (en) | Chimerical receptor containing TRAF inducement structures domain and compositions related and method | |
KR20160101947A (en) | Tagged chimeric effector molecules and receptors thereof | |
CN110139669A (en) | The combination treatment of T cell therapy and BTK inhibitor | |
CN107074936A (en) | Anti- galactose agglutinin 9 and be regulatory T cells inhibitory activity inhibitor antibody | |
CN110678197A (en) | Method of producing a composite material | |
JP2020526194A (en) | Mouse model for assessing toxicity associated with immunotherapeutic agents | |
CN113543807A (en) | anti-TCR antibody molecules and uses thereof | |
US20230048244A1 (en) | Anti-tcr antibody molecules and uses thereof | |
Liebman et al. | Antibody treatment of human tumor xenografts elicits active anti-tumor immunity in nude mice | |
COLOMAR CARANDO | Novel insights into NK cell/leukemia molecular interactions and possible tools to potentiate the anti-leukemia NK cell activity | |
Snyder | Augmenting Natural Killer Cell Antibody Binding to Enhance Ovarian and Prostate Tumor Cell Killing via ADCC | |
Maggs | The role of stem cell graft derived natural killer cells in regulating patient outcomes from allogeneic haematopoietic stem cell transplantation | |
Tse | Novel immunotherapy for paediatric cancers | |
Grupp et al. | Immunotherapy for pediatric cancer | |
EFFECTOR et al. | Natural Killer Cell Effector Mechanisms Against Solid Tumors and Leukemias and Their Exploitation in Immunotherapy | |
Rouas-Freiss et al. | Evidence to Support the Role of HLA-G5 in | |
Engelhardt | Induction of functional human macrophages in humanized mice |